Subpotent Injection Recalled

IntegraDose Compounding Services is recalling 1299 syringes containing vasopressin in 0.9% sodium chloride that were distributed in Minnesota. According to the February 21, 2024, US Food and Drug Administration (FDA) Enforcement Report, the drug is subpotent.

The recall affects vasopressin 2 units/2 mL in 0.9% sodium chloride sterile syringe for injection, concentration 1 unit/mL, 2-mL syringe (NDC 71139-0190-1), from lots 20230929VAS-2 (Exp. 2/29/24), 20231004VAS-2 (Exp. 4/1/24), 20231010VAS-2 (Exp. 4/7/24), and 20231013VAS-2 (Exp. 4/10/24).

IntegraDose Compounding Services voluntarily initiated the recall January 22, 2024. The FDA designated the recall Class II on February 15, 2024. Per the recall classification, use of the affected product may cause temporary or medically reversible adverse health consequences. While remote, a possibility of serious harm also exists.

Vasopressin in 0.9% sodium chloride is a human compounded drug. Compounded drugs are created by combining or altering existing medications to meet the needs of specific patients.